Crinetics Pharmaceuticals Inc’s filing revealed that its Chief Med and Dev Officer Pizzuti Dana unloaded Company’s shares for reported $86021.0 on Mar 19 ’25. In the deal valued at $34.20 per share,2,515 shares were sold. As a result of this transaction, Pizzuti Dana now holds 72,233 shares worth roughly $2.13 million.
Then, Knight Jeff E. sold 7,162 shares, generating $244,964 in total proceeds. Upon selling the shares at $34.20, the Chief Operating Officer now owns 87,491 shares.
Before that, Betz Stephen F. sold 5,770 shares. Crinetics Pharmaceuticals Inc shares valued at $197,353 were divested by the Chief Scientific Officer at a price of $34.20 per share. As a result of the transaction, Betz Stephen F. now holds 108,588 shares, worth roughly $3.2 million.
Stifel initiated its Crinetics Pharmaceuticals Inc [CRNX] rating to a Buy in a research note published on March 25, 2025; the price target was $60. A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in mid February with a ‘”a Buy”‘ rating. Wolfe Research began covering CRNX with “Peer perform” recommendation on February 04, 2025. Jefferies revised its rating on January 22, 2025. It rated CRNX as “a Buy” which previously was an “a Hold”.
Price Performance Review of CRNX
On Tuesday, Crinetics Pharmaceuticals Inc [NASDAQ:CRNX] saw its stock fall -0.87% to $29.50. Over the last five days, the stock has lost -4.68%. Crinetics Pharmaceuticals Inc shares have fallen nearly -42.30% since the year began. Nevertheless, the stocks have fallen -41.63% over the past one year. While a 52-week high of $62.53 was reached on 01/03/25, a 52-week low of $24.10 was recorded on 04/09/25. SMA at 50 days reached $31.59, while 200 days put it at $44.71.
Levels Of Support And Resistance For CRNX Stock
The 24-hour chart illustrates a support level at 28.96, which if violated will result in even more drops to 28.43. On the upside, there is a resistance level at 30.12. A further resistance level may holdings at 30.75. The Relative Strength Index (RSI) on the 14-day chart is 41.58, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.24, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 91.49%. Stochastics %K at 7.00% indicates the stock is a buying.
The most recent change occurred on March 06, 2024 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $68 price target.
